COVID 19
Following updated Government and Health Authority advice, to reduce the spread of COVID 19 and to reduce any risks to our employees, all employees across the Group are working from home, aside from those critical to the continued manufacture of our products. As part of our commitment to putting patients first, we are continually monitoring our supply chain and manufacturing capabilities and are confident that we will continue to be able to supply our allergy therapies and diagnostics. We continue to monitor the situation and are committed to maintain our mission of transforming allergy treatment.
Our year in numbers
2019 was a year of continued growth with constant currency growth of 8%, a 0.5 point increase in our market share to 14.1% and an increase in operating profit before R&D of 22%.
Annual Report 2019
Allergies reduce quality of life by preventing individuals and their loved ones from enjoying the everyday activities most take for granted. At their most severe, they can be fatal.
Transforming lives
Specialist expertise drives and inspires us to discover more, helping us to improve patients' lives.
Specialist expertise
To achieve our vision and fulfil our mission, we develop treatments that are as convenient as they are effective.
Delivering convenience
Take your career to new heights
Our culture and values